Galmed Pharmaceuticals Financials
| GLMD Stock | USD 2.82 0.10 3.42% |
Galmed |
Understanding current and past Galmed Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Galmed Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Galmed Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Galmed Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Galmed Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Galmed Pharmaceuticals' management manipulating its earnings.
Galmed Pharmaceuticals Stock Summary
Galmed Pharmaceuticals competes with Affimed NV, Abeona Therapeutics, Akebia Ther, Kodiak Sciences, and Mereo BioPharma. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | IL0011313900 |
| CUSIP | M47238106 M47238122 M47238148 |
| Location | Israel |
| Business Address | 16 Abba Hillel |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.galmedpharma.com |
| Phone | 972 3 693 8448 |
| Currency | USD - US Dollar |
Galmed Pharmaceuticals Key Financial Ratios
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.29 | ||||
| Target Price | 12.0 | ||||
| Beta | 0.8 |
Galmed Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Galmed Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Galmed Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Galmed Pharmaceuticals competition to find correlations between indicators driving Galmed Pharmaceuticals's intrinsic value. More Info.Galmed Pharmaceuticals is rated # 3 in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Galmed Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Galmed Pharmaceuticals Systematic Risk
Galmed Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Galmed Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Galmed Pharmaceuticals correlated with the market. If Beta is less than 0 Galmed Pharmaceuticals generally moves in the opposite direction as compared to the market. If Galmed Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Galmed Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Galmed Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Galmed Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
About Galmed Pharmaceuticals Financials
What exactly are Galmed Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Galmed Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Galmed Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Galmed Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Galmed Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Galmed Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Galmed Pharmaceuticals January 30, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Galmed Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Galmed Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Galmed Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Galmed Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Galmed Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 22.05 | |||
| Value At Risk | (7.25) | |||
| Potential Upside | 5.32 |
Complementary Tools for Galmed Stock analysis
When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |